Veradigm (MDRX) 10-Q 6 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1,124,804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		187,071,249

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 100,116	$ 116,873
Accounts receivable, net of allowance of $32,701 and $31,266 as of March 31, 2016 and December 31, 2015, respectively	340,091	327,851
Prepaid expenses and other current assets	99,127	93,622
Total current assets	539,334	538,346
Fixed assets, net	117,679	125,617
Software development costs, net	86,113	85,775
Intangible assets, net	335,722	347,646
Goodwill	1,222,283	1,222,601
Deferred taxes, net	2,414	2,298
Other assets	320,777	359,665
Total assets	2,624,322	2,681,948
Current liabilities:
Accounts payable	71,530	60,004
Accrued expenses	56,007	62,021
Accrued compensation and benefits	37,525	62,398
Deferred revenue	365,415	315,925
Current maturities of long-term debt and capital lease obligations	12,430	12,609
Total current liabilities	542,907	512,957
Long-term debt	587,388	612,405
Deferred revenue	20,001	20,273
Deferred taxes, net	23,267	22,164
Other liabilities	61,492	95,076
Total liabilities	$ 1,235,055	$ 1,262,875
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of March 31, 2016 and December 31, 2015	$ 0	$ 0
Common stock: $0.01 par value, 349,000 shares authorized as of March 31, 2016 and December 31, 2015; 267,161 and 186,974 shares issued and outstanding as of March 31, 2016, respectively; 266,545 and 189,308 shares issued and outstanding as of December 31, 2015, respectively	2,672	2,665
Treasury stock: at cost, 80,186 and 77,237 shares as of March 31, 2016 and December 31, 2015, respectively	(227,270)	(189,753)
Additional paid-in capital	1,794,015	1,789,449
Accumulated deficit	(188,186)	(190,235)
Accumulated other comprehensive loss	(3,231)	(4,242)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,378,000	1,407,884
Non-controlling interest	11,267	11,189
Total stockholders’ equity	1,389,267	1,419,073
Total liabilities and stockholders’ equity	$ 2,624,322	$ 2,681,948

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 32,701	$ 31,266
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	267,161,000	266,545,000
Common stock, shares outstanding	186,974,000	189,308,000
Treasury stock at cost, shares	80,186,000	77,237,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Software delivery, support and maintenance	$ 229,158	$ 227,559
Client services	116,400	106,993
Total revenue	345,558	334,552
Cost of revenue:
Software delivery, support and maintenance	75,169	76,687
Client services	100,859	107,159
Amortization of software development and acquisition-related assets	17,632	20,916
Total cost of revenue	193,660	204,762
Gross profit	151,898	129,790
Selling, general and administrative expenses	84,153	82,029
Research and development	47,037	46,727
Asset impairment charges	4,650	26
Amortization of intangible and acquisition-related assets	4,162	6,703
Income (loss) from operations	11,896	(5,695)
Interest expense	(6,969)	(7,256)
Other income, net	366	1,886
Equity in net earnings of unconsolidated investments	(2,603)	0
Income (loss) before income taxes	2,690	(11,065)
Income tax (provision) benefit	(563)	981
Net income (loss)	2,127	(10,084)
Less: Net income attributable to non-controlling interest	(78)	0
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 2,049	$ (10,084)
Earnings (loss) per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 0.01	$ (0.06)
Earnings (loss) per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 0.01	$ (0.06)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 2,127	$ (10,084)
Other comprehensive income (loss):
Foreign currency translation adjustments	744	(1,067)
Change in unrealized gains on marketable securities	0	(228)
Change in fair value of derivatives qualifying as cash flow hedges	441	0
Other comprehensive income (loss) before income tax expense	1,185	(1,295)
Income tax benefit (expense) related to items in other comprehensive income (loss)	(174)	88
Total other comprehensive income (loss)	1,011	(1,207)
Comprehensive income (loss)	3,138	(11,291)
Less: Comprehensive income attributable to non-controlling interest	(78)	0
Comprehensive income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 3,060	$ (11,291)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ 2,127	$ (10,084)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	34,452	41,661
Stock-based compensation expense	9,919	9,120
Excess tax benefits from stock-based compensation	(197)	(2)
Deferred taxes	(362)	(949)
Asset impairment charges	4,650	26
Other losses, net	3,059	965
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable, net	(12,250)	5,244
Prepaid expenses and other assets	(1,815)	(1,960)
Accounts payable	16,997	11,817
Accrued expenses	(5,165)	(15,365)
Accrued compensation and benefits	(24,929)	(11,136)
Deferred revenue	49,393	29,240
Other liabilities	54	(47)
Net cash provided by operating activities	75,933	58,530
Cash flows from investing activities:
Capital expenditures	(7,752)	(6,115)
Capitalized software	(15,134)	(9,315)
Purchase of controlling interest, net of cash acquired	0	0
Purchases of non-marketable securities, other investments and related intangible assets	(500)	(750)
Sales and maturities of marketable securities and other investments	0	1,305
Proceeds received from sale of fixed assets	11	7
Net cash used in investing activities	(23,375)	(14,868)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	5	40
Excess tax benefits from stock-based compensation	197	2
Taxes paid related to net share settlement of equity awards	(4,146)	(2,207)
Payments of capital lease obligations	(239)	(68)
Credit facility payments	(28,164)	(20,625)
Credit facility borrowings	0	15,000
Repurchase of common stock	(37,517)	0
Net cash used in financing activities	(69,864)	(7,858)
Effect of exchange rate changes on cash and cash equivalents	549	(497)
Net (decrease) increase in cash and cash equivalents	(16,757)	35,307
Cash and cash equivalents, beginning of period	116,873	53,173
Cash and cash equivalents, end of period	$ 100,116	$ 88,480

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and majority-owned affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and majority-owned subsidiaries, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year ending December 31, 2016. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Accounting Pronouncements Not yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic In March 2016, the FASB issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Fair Value Measurements and Inv

Fair Value Measurements and Investments	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements and Investments	2. Fair Value Measurements and Investments We carry a portion of our financial assets and liabilities at fair value that are measured at a reporting date using an exit price (i.e., the price that would be received to sell an asset or paid to transfer a liability) and disclosed according to the quality of valuation inputs under the following hierarchy: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 9, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 9, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2016 December 31, 2015 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 49,005 $ 49,005 $ 0 $ - $ 80,208 $ 80,208 1.25% Embedded cash conversion option Other liabilities 0 0 (49,817 ) (49,817 ) 0 0 (81,210 ) (81,210 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 866 0 866 0 424 0 424 Foreign exchange derivative liabilities Accrued expenses 0 0 0 0 0 0 0 0 Total $ 0 $ 866 $ (812 ) $ 54 $ 0 $ 424 $ (1,002 ) $ (578 ) Investments The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Original Carrying Value at (In thousands) Investees Investment March 31, 2016 December 31, 2015 Equity method investments (1): Nant Health, LLC 1 $ 205,393 $ 200,514 $ 203,117 Other 3 1,658 2,436 2,436 Total equity method investments 4 207,051 202,950 205,553 Cost method investments 3 19,776 15,826 17,876 Total equity investments 7 $ 226,827 $ 218,776 $ 223,429 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. The decline in the carrying value of our equity method investments from December 31, 2015 to March 31, 2016 was primarily due to the recognition of $2.6 million representing our equity share of the net losses of our investees for the period and the amortization of cost basis differences. The carrying amount of our equity method investment in Nant Health, LLC (“NantHealth”) at March 31, 2016 exceeded the amount of our share of underlying equity in net assets of NantHealth at December 31, 2015 by $182.0 million. The excess carrying value over the underlying equity in net assets of NantHealth is primarily comprised of amortizable intangible assets and nonamortizable goodwill. The decline in the carrying value of our cost method investments from December 31, 2015 to March 31, 2016 was primarily due to the recognition of an impairment charge of $2.1 million on one investment during the first quarter of 2016. As of March 31, 2016, i . During first quarter of 2016, we acquired a $0.5 million non-marketable convertible note of a third party with which we have an existing license and distribution agreement. This investment is accounted as an available-for-sale security with changes in fair value recorded in accumulated other comprehensive loss. The fair value of the convertible note was $0.5 million as of March 31, 2016 and was included in other assets in the accompanying consolidated balance sheet as of March 31, 2016. Summarized Financial Information for Equity Method Investments Summarized financial information for our equity method investments on an aggregated basis since the date of acquisition is as follows: December 31, September 30, (In thousands) 2015 2015 Current assets $ 42,239 $ 58,550 Noncurrent assets 397,519 411,159 Current liabilities 52,482 77,188 Noncurrent liabilities 191,563 166,898 Equity of equity method investments $ 195,713 $ 225,623 (In thousands) Trailing Three Months Ended December 31, 2015 Trailing Three Months Ended December 31, 2014 Revenue $ 23,336 $ 2,470 Net loss (24,540 ) (216 ) Long-Term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility, with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of March 31, 2016, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 7, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity	3. Stockholders' Equity Stock-based Awards We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three months ended March 31, 2016 and 2015. Stock-based compensation expense recognized during the three months ended March 31, 2016 and 2015 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three months ended March 16, 2016 and 2015. Three Months Ended March 31, (In thousands) 2016 2015 Cost of revenue: Software delivery, support and maintenance $ 1,169 $ 1,096 Client services 1,490 1,408 Total cost of revenue 2,659 2,504 Selling, general and administrative expenses 5,166 5,011 Research and development 2,576 2,003 Total stock-based compensation expense $ 10,401 $ 9,518 We granted stock-based awards as follows: Three Months Ended March 31, 2016 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 1,802 $ 13.13 Performance-based restricted stock units with a service condition 545 $ 12.39 Market-based restricted stock units with a service condition 621 $ 13.49 2,968 $ 13.07 During the three months ended March 31, 2016 and the year ended December 31, 2015, 0.6 million and 1.4 million shares of stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Beginning in 2011, upon vesting, restricted stock units and awards are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested in 2016 and 2015 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2016 and 2015 were 323 thousand and 179 thousand, respectively, and were based on the value of the restricted stock units and awards on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases In November 2015, our Board of Directors authorized a stock repurchase program under which we may repurchase up to $150 million of our common stock through December 31, 2018. Any share repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time. During the three months ended March 31, 2016, we repurchased 2.9 million shares of our common stock for $37.5 million pursuant to this stock repurchase program. As of March 31, 2016, the amount available for repurchase of common stock under this program was $112.5 million.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	4. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2016 2015 Basic Earnings (Loss) per Common Share: Net income (loss) $ 2,127 $ (10,084 ) Less: Net income attributable to non-controlling interest $ (78 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 2,049 $ (10,084 ) Weighted-average common shares outstanding 188,561 180,581 Basic Earnings (Loss) per Common Share $ 0.01 $ (0.06 ) Diluted Earnings (Loss) per Common Share: Net income (loss) $ 2,127 $ (10,084 ) Less: Net income attributable to non-controlling interest $ (78 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 2,049 $ (10,084 ) Weighted-average common shares outstanding 188,561 180,581 Dilutive effect of stock options, restricted stock unit awards and warrants 2,180 0 Weighted-average common shares outstanding assuming dilution 190,741 180,581 Diluted Earnings (Loss) per Common Share $ 0.01 $ (0.06 ) As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three months ended March 31, 2015, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2016 2015 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 25,201 25,144

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	5. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: March 31, 2016 December 31, 2015 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 450,692 $ (309,721 ) $ 140,971 $ 450,852 $ (302,284 ) $ 148,568 Customer contracts and relationships 552,200 (409,449 ) 142,751 552,395 (405,317 ) 147,078 Total $ 1,002,892 $ (719,170 ) $ 283,722 $ 1,003,247 $ (707,601 ) $ 295,646 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,222,283 1,222,601 Total $ 1,274,283 $ 1,274,601 Effective January 1, 2016, we made an organizational change within our Clinical and Financial Solutions reportable segment. Refer to Note 12, “Business Segments” for additional information. As a result of this organizational change, we assessed our revised reporting units and allocated the goodwill previously assigned to our former Touchworks reporting unit to our new Acute and Ambulatory reporting units based on the relative fair value allocation method as applied to the separate Touchworks acute and ambulatory businesses. We performed our annual goodwill impairment test as of October 1, 2015, our annual testing date, and again as of January 1, 2016 in conjunction with the organizational change within our Clinical and Financial Solutions reportable segment. The January 1, 2016 goodwill impairment test was performed on a before and after basis, which included impairment tests for each of the separate Touchworks acute and ambulatory businesses and for each of the new Acute and Ambulatory reporting units. The fair values of the separate Touchworks acute and ambulatory businesses and of the Acute and Ambulatory reporting unit substantially exceeded their carrying values and no indicators of impairment were identified as a result of each of these goodwill impairment tests. Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2016 were as follows: Clinical and Population (In thousands) Financial Solutions Health Total Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 1,222,601 Foreign exchange translation (318 ) 0 (318 ) Balance as of March 31, 2016 $ 796,049 $ 426,234 $ 1,222,283 There were no accumulated impairment losses associated with our goodwill as of March 31, 2016 or December 31, 2015.

Asset Impairment Charges

Asset Impairment Charges	3 Months Ended
	Mar. 31, 2016
Asset Impairment Charges [Abstract]
Asset Impairment Charges	6. Asset Impairment Charges During the first quarter of 2016, we incurred non-cash asset impairment charges totaling $4.7 million. Included in these charges was $2.2 million for the impairment of capitalized software as a result of our decision to discontinue several software development projects, $2.1 million for the impairment of one of our cost method equity investments, and other charges of $0.4 million to write down a long-term asset to its estimated net realizable value. Asset impairment charges for the first quarter of 2015 were not significant.

Debt

Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt	7. Debt Debt outstanding, excluding capital leases, consisted of the following: March 31, 2016 December 31, 2015 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 58,663 $ 286,337 $ 345,000 $ 61,771 $ 283,229 Senior Secured Credit Facility (long-term portion) 306,250 5,232 301,018 334,375 5,225 329,150 Senior Secured Credit Facility (current portion) 12,500 473 12,027 12,500 479 12,021 Other debt 144 0 144 183 0 183 Total debt $ 663,894 $ 64,368 $ 599,526 $ 692,058 $ 67,475 $ 624,583 Interest expense consisted of the following: Three Months Ended March 31, (In thousands) 2016 2015 Interest expense $ 3,538 $ 3,861 Amortization of discounts and debt issuance costs 3,431 3,395 Total interest expense $ 6,969 $ 7,256 Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended March 31, (In thousands) 2016 2015 Coupon interest at 1.25% $ 1,078 $ 1,078 Amortization of discounts and debt issuance costs 3,108 2,948 Total interest expense related to the 1.25% Notes $ 4,186 $ 4,026 Senior Secured Credit Facility Amendment On March 28, 2016, we entered into a First Amendment with JPMorgan Chase Bank, N.A., as administrative agent, and certain other lenders to our senior secured credit facility agreement executed on September 30, 2015. This amendment allows us greater flexibility to make selective cash investments in third parties while continuing to remain in compliance with the original covenants of our senior secured credit facility agreement. In addition, this amendment clarifies certain definitions and clauses contained in our original senior secured credit facility agreement. None of the original terms of our senior secured credit facility relating to scheduled future principal payments, applicable interest rates and margins, and borrowing capacity under our revolving facility were amended. In connection with this amendment, we incurred fees and other costs totaling $0.3 million, which were capitalized and included in the net carrying amounts outstanding under our senior secured credit facility as of March 31, 2016. The capitalized fees and other costs will be amortized to interest expense over the remaining term of our senior secured credit facility. As of March 31, 2016, $243.8 million under a term loan, $75.0 million under our revolving credit facility, and $0.7 million in letters of credit were outstanding under our senior secured credit facility. As of March 31, 2016, the interest rate on the United States dollars-denominated borrowings under the senior secured credit facility was LIBOR plus 1.75%, which totaled 2.18%. We were in compliance with all covenants under the senior secured credit facility agreement as of March 31, 2016. As of March 31, 2016, we had $474.3 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our revolving credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. As of March 31, 2016, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. The following table summarizes our future payment obligations under the 1.25% Notes and our senior secured credit facility as of March 31, 2016: (In thousands) Total Remainder of 2016 2017 2018 2019 2020 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 Term Loan 243,750 9,375 15,625 28,125 40,625 150,000 Revolving Facility 75,000 0 0 0 0 75,000 Other debt 144 144 0 0 0 0 Total debt $ 663,894 $ 9,519 $ 15,625 $ 28,125 $ 40,625 $ 570,000 (1)

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes Three Months Ended March 31, (In thousands) 2016 2015 Income (loss) before income taxes $ 2,690 $ (11,065 ) Income tax (provision) benefit $ (563 ) $ 981 Effective tax rate 20.9 % 8.9 % Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended March 31, 2016, compared with the prior year comparable period, differs primarily due to the fact that t he income tax (provision) benefit for the three months ended March 31, 2015 did not include any tax benefit for year to date losses due to our estimate of income at that time for overall annual results of operation for 2015. Additionally, no estimate of the research and development credit was included in the effective tax rate for the three months ended March 31, 2015 as the credit had not been reinstated for 2015 until December 18, 2015. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Due to the level of forecasted operating income for the year ending December 31, 2016, we released $0.9 million of valuation allowance during the three months ended March 31, 2016 related to deferred tax assets associated with net operating loss carryforwards. Our unrecognized income tax benefits were $12.3 million and $11.8 million as of March 31, 2016 and December 31, 2015, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	9. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 866 Accrued expenses $ - Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 49,005 N/A 1.25% Embedded cash conversion option N/A Other liabilities 49,817 Total derivatives $ 49,871 $ 49,817 December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ - Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts In 2015, we entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of March 31, 2016, there were 30 forward contracts outstanding that were staggered to mature monthly starting in April 2016 and ending in December 2017. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2017. As of March 31, 2016, the notional amounts of outstanding forward contracts ranged from 20 million to 140 million INR, or the equivalent of $0.3 million to $2.1 million, based on the exchange rate between the United States dollar and the INR in effect as of March 31, 2016. These amounts also approximate the ranges of forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three months ended March 31, 2016, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of March 31, 2016, we estimate that $0.7 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months ended March 31, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months ended March 31, 2016 Foreign exchange contracts $ 342 Cost of Revenue $ (31 ) Selling, general and administrative expenses (25 ) Research and development (43 ) Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months ended March 31, 2015 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months ended March 31, 2015 Foreign exchange contracts $ 0 Cost of Revenue $ 0 Selling, general and administrative expenses 0 Research and development 0 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 2, “Fair Value Measurements and Investments.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 2, “Fair Value Measurements and Investments.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2016 2015 1.25% Call Option $ (31,203 ) $ (7,209 ) 1.25% Embedded cash conversion option 31,393 7,234 Net gain (loss) included in other income, net $ 190 $ 25

Other Comprehensive Income

Other Comprehensive Income	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Other Comprehensive Income	10. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications 744 0 207 951 Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 60 60 Net other comprehensive (loss) income 744 0 267 1,011 Balance as of March 31, 2016 (2) $ (3,756 ) $ 0 $ 525 $ (3,231 ) (1) (2) (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2014 (1) $ (2,119 ) $ 140 $ 0 $ (1,979 ) Other comprehensive income (loss) before reclassifications (1,067 ) 0 0 (1,067 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 (140 ) 0 (140 ) Net other comprehensive income (1,067 ) (140 ) 0 (1,207 ) Balance as of March 31, 2015 $ (3,186 ) $ 0 $ 0 $ (3,186 ) (1 ) Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 744 $ 0 $ 744 $ (1,067 ) $ 0 $ (1,067 ) Marketable securities: Net gain arising during the period 0 0 0 0 0 0 Net gain reclassified into income 0 0 0 (228 ) 88 (140 ) Net change in unrealized gains on marketable securities 0 0 0 (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 342 (135 ) 207 0 0 0 Net (gains) losses reclassified into income 99 (39 ) 60 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 441 (174 ) 267 0 0 0 Net gain (loss) on cash flow hedges 441 (174 ) 267 0 0 0 Other comprehensive (loss) income $ 1,185 $ (174 ) $ 1,011 $ (1,295 ) $ 88 $ (1,207 )

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Contingencies	11. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results. In the opinion of our management, based on the information currently available, there was not at least a reasonable possibility that we may have incurred any material loss, or any material loss in excess of a recorded accrual, with respect to the following matters. Our management will continue to evaluate the potential exposure related to these matters in future periods. On September 14, 2010, Pegasus Imaging Corporation filed a complaint against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to the plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation. On July 7, 2014, the Court granted our motion for summary judgment on the plaintiff’s claim of unfair trade practices under Florida law and our motion for summary judgment as to the aforementioned defunct corporations, and granted the plaintiff’s motion for summary judgment on our counterclaims, for which the plaintiff has moved for reconsideration. A hearing to hear the plaintiff’s motions was held September 21 and 22, 2015, and we are awaiting a ruling. No trial date has been scheduled. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in U.S. District Court for the Northern District of Illinois against us. The complaint alleges that on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA; treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. After plaintiff’s motion to compel arbitration of the counterclaims was granted, Allscripts made a demand in arbitration where the counterclaims remain pending. Discovery in the proposed class action has now concluded. On March 31, 2016, plaintiff filed its motion for class certification. Other Matters On May 2, 2012, a lawsuit was filed in the United States District Court for the Northern District of Illinois against us; Glen Tullman, our former Chief Executive Officer; and William Davis, our former Chief Financial Officer, by the Bristol County Retirement System for itself and on behalf of a purported class consisting of stockholders who purchased our common stock between November 18, 2010 and April 26, 2012. In April 2015, the Court granted a motion for preliminary approval of the class settlement in this lawsuit and on July 21, 2015, the Court approved the settlement and entered a final judgment binding on members of the class, minus stockholders who excluded themselves from the settlement, including certain entities affiliated with HealthCor Management, L.P. On March 29, 2016, we reached a settlement with the stockholders who had excluded themselves from the class settlement, and this matter is now resolved.

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Business Segments	12. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as, outsourcing, remote hosting and revenue cycle management. In an effort to further streamline and align our operating structure around our key ambulatory and acute products, effective January 1, 2016, we made changes to our organizational and reporting structure. These changes included (i) the separation of the former Touchworks strategic business unit and its separate leadership team into acute and ambulatory businesses, and (ii) the transfer of several ancillary analytics-type products between our two existing reportable segments. In conjunction with these changes, we formed new Ambulatory and Acute strategic business units, which are deemed to be operating segments within the Clinical and Financial Solutions reportable segment. The ancillary products are extensions of our key ambulatory and acute solutions and in the future will be managed within the new Ambulatory and Acute strategic business units. The prior period segment disclosures below were revised to conform to the current year presentation. After the finalization of the above changes to our organizational and reporting structure, effective January 1, 2016, we had four operating segments which are aggregated into our two existing reportable segments. The Clinical and Financial Solutions reportable segment includes the new Ambulatory and Acute, and the Payer and Life Sciences strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include Electronic Health Record-related software, financial and practice management software, related installation, support and maintenance, outsourcing, hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of a single strategic business unit, which represents a separate operating segment, and derives its revenue from the sale of health management and coordinated care solutions, which are mainly targeted at hospitals, health systems, other care facilities and Accountable Care Organizations. These solutions enable clients to connect, transition, analyze, and coordinate care across the entire care community. Our CODM uses segment revenues, gross profit and income from operations as measures of performance and to allocate resources. In determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. We exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting, and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware. We do not track our assets by segment. Three Months Ended March 31, (In thousands) 2016 2015 Revenue: Clinical and Financial Solutions $ 271,654 $ 263,875 Population Health 66,383 64,948 Unallocated Amounts 7,521 5,729 Total revenue $ 345,558 $ 334,552 Gross Profit: Clinical and Financial Solutions $ 114,200 $ 98,273 Population Health 48,995 43,199 Unallocated Amounts (11,297 ) (11,682 ) Total gross profit $ 151,898 $ 129,790 Income (loss) from operations: Clinical and Financial Solutions $ 61,017 $ 43,185 Population Health 32,834 26,247 Unallocated Amounts (81,955 ) (75,127 ) Total income (loss) from operations $ 11,896 $ (5,695 )

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On March 20, 2016, we entered into a Contribution and Investment Agreement with GI Netsmart Holdings LLC, a Delaware limited liability company, Andrews Henderson LLC, a Delaware limited liability company, and Nathan Holding LLC, a Delaware limited liability company to form a joint venture (the “Netsmart JV”). The establishment of the Netsmart JV, combining our Allscripts Homecare TM

Basis of Presentation and Sig20

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and majority-owned affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and majority-owned subsidiaries, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year ending December 31, 2016. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic In March 2016, the FASB issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Fair Value Measurements and I21

Fair Value Measurements and Investments (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2016 December 31, 2015 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 49,005 $ 49,005 $ 0 $ - $ 80,208 $ 80,208 1.25% Embedded cash conversion option Other liabilities 0 0 (49,817 ) (49,817 ) 0 0 (81,210 ) (81,210 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 866 0 866 0 424 0 424 Foreign exchange derivative liabilities Accrued expenses 0 0 0 0 0 0 0 0 Total $ 0 $ 866 $ (812 ) $ 54 $ 0 $ 424 $ (1,002 ) $ (578 )
Summary of Equity Investments Included in Other Assets	The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Original Carrying Value at (In thousands) Investees Investment March 31, 2016 December 31, 2015 Equity method investments (1): Nant Health, LLC 1 $ 205,393 $ 200,514 $ 203,117 Other 3 1,658 2,436 2,436 Total equity method investments 4 207,051 202,950 205,553 Cost method investments 3 19,776 15,826 17,876 Total equity investments 7 $ 226,827 $ 218,776 $ 223,429 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.
Summarized Financial Information for Equity Method Investments	Summarized financial information for our equity method investments on an aggregated basis since the date of acquisition is as follows: December 31, September 30, (In thousands) 2015 2015 Current assets $ 42,239 $ 58,550 Noncurrent assets 397,519 411,159 Current liabilities 52,482 77,188 Noncurrent liabilities 191,563 166,898 Equity of equity method investments $ 195,713 $ 225,623 (In thousands) Trailing Three Months Ended December 31, 2015 Trailing Three Months Ended December 31, 2014 Revenue $ 23,336 $ 2,470 Net loss (24,540 ) (216 ) Long-Term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility, with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of March 31, 2016, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 7, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stock-Based Compensation Expense	Stock-based compensation expense recognized during the three months ended March 31, 2016 and 2015 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three months ended March 16, 2016 and 2015. Three Months Ended March 31, (In thousands) 2016 2015 Cost of revenue: Software delivery, support and maintenance $ 1,169 $ 1,096 Client services 1,490 1,408 Total cost of revenue 2,659 2,504 Selling, general and administrative expenses 5,166 5,011 Research and development 2,576 2,003 Total stock-based compensation expense $ 10,401 $ 9,518
Stock-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended March 31, 2016 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 1,802 $ 13.13 Performance-based restricted stock units with a service condition 545 $ 12.39 Market-based restricted stock units with a service condition 621 $ 13.49 2,968 $ 13.07

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2016 2015 Basic Earnings (Loss) per Common Share: Net income (loss) $ 2,127 $ (10,084 ) Less: Net income attributable to non-controlling interest $ (78 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 2,049 $ (10,084 ) Weighted-average common shares outstanding 188,561 180,581 Basic Earnings (Loss) per Common Share $ 0.01 $ (0.06 ) Diluted Earnings (Loss) per Common Share: Net income (loss) $ 2,127 $ (10,084 ) Less: Net income attributable to non-controlling interest $ (78 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 2,049 $ (10,084 ) Weighted-average common shares outstanding 188,561 180,581 Dilutive effect of stock options, restricted stock unit awards and warrants 2,180 0 Weighted-average common shares outstanding assuming dilution 190,741 180,581 Diluted Earnings (Loss) per Common Share $ 0.01 $ (0.06 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2016 2015 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 25,201 25,144

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: March 31, 2016 December 31, 2015 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 450,692 $ (309,721 ) $ 140,971 $ 450,852 $ (302,284 ) $ 148,568 Customer contracts and relationships 552,200 (409,449 ) 142,751 552,395 (405,317 ) 147,078 Total $ 1,002,892 $ (719,170 ) $ 283,722 $ 1,003,247 $ (707,601 ) $ 295,646 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,222,283 1,222,601 Total $ 1,274,283 $ 1,274,601
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2016 were as follows: Clinical and Population (In thousands) Financial Solutions Health Total Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 1,222,601 Foreign exchange translation (318 ) 0 (318 ) Balance as of March 31, 2016 $ 796,049 $ 426,234 $ 1,222,283

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt Outstanding Excluding Capital Leases	Debt outstanding, excluding capital leases, consisted of the following: March 31, 2016 December 31, 2015 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 58,663 $ 286,337 $ 345,000 $ 61,771 $ 283,229 Senior Secured Credit Facility (long-term portion) 306,250 5,232 301,018 334,375 5,225 329,150 Senior Secured Credit Facility (current portion) 12,500 473 12,027 12,500 479 12,021 Other debt 144 0 144 183 0 183 Total debt $ 663,894 $ 64,368 $ 599,526 $ 692,058 $ 67,475 $ 624,583
Interest Expense	Interest expense consisted of the following: Three Months Ended March 31, (In thousands) 2016 2015 Interest expense $ 3,538 $ 3,861 Amortization of discounts and debt issuance costs 3,431 3,395 Total interest expense $ 6,969 $ 7,256
Interest Expense Related to Notes	Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended March 31, (In thousands) 2016 2015 Coupon interest at 1.25% $ 1,078 $ 1,078 Amortization of discounts and debt issuance costs 3,108 2,948 Total interest expense related to the 1.25% Notes $ 4,186 $ 4,026
Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities	The following table summarizes our future payment obligations under the 1.25% Notes and our senior secured credit facility as of March 31, 2016: (In thousands) Total Remainder of 2016 2017 2018 2019 2020 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 Term Loan 243,750 9,375 15,625 28,125 40,625 150,000 Revolving Facility 75,000 0 0 0 0 75,000 Other debt 144 144 0 0 0 0 Total debt $ 663,894 $ 9,519 $ 15,625 $ 28,125 $ 40,625 $ 570,000 (1)

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Effective Tax Rates	Three Months Ended March 31, (In thousands) 2016 2015 Income (loss) before income taxes $ 2,690 $ (11,065 ) Income tax (provision) benefit $ (563 ) $ 981 Effective tax rate 20.9 % 8.9 %

Derivative Financial Instrume27

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 866 Accrued expenses $ - Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 49,005 N/A 1.25% Embedded cash conversion option N/A Other liabilities 49,817 Total derivatives $ 49,871 $ 49,817 December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ - Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months ended March 31, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months ended March 31, 2016 Foreign exchange contracts $ 342 Cost of Revenue $ (31 ) Selling, general and administrative expenses (25 ) Research and development (43 ) Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months ended March 31, 2015 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months ended March 31, 2015 Foreign exchange contracts $ 0 Cost of Revenue $ 0 Selling, general and administrative expenses 0 Research and development 0
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2016 2015 1.25% Call Option $ (31,203 ) $ (7,209 ) 1.25% Embedded cash conversion option 31,393 7,234 Net gain (loss) included in other income, net $ 190 $ 25

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications 744 0 207 951 Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 60 60 Net other comprehensive (loss) income 744 0 267 1,011 Balance as of March 31, 2016 (2) $ (3,756 ) $ 0 $ 525 $ (3,231 ) (1) (2) (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2014 (1) $ (2,119 ) $ 140 $ 0 $ (1,979 ) Other comprehensive income (loss) before reclassifications (1,067 ) 0 0 (1,067 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 (140 ) 0 (140 ) Net other comprehensive income (1,067 ) (140 ) 0 (1,207 ) Balance as of March 31, 2015 $ (3,186 ) $ 0 $ 0 $ (3,186 ) (1 )
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 744 $ 0 $ 744 $ (1,067 ) $ 0 $ (1,067 ) Marketable securities: Net gain arising during the period 0 0 0 0 0 0 Net gain reclassified into income 0 0 0 (228 ) 88 (140 ) Net change in unrealized gains on marketable securities 0 0 0 (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 342 (135 ) 207 0 0 0 Net (gains) losses reclassified into income 99 (39 ) 60 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 441 (174 ) 267 0 0 0 Net gain (loss) on cash flow hedges 441 (174 ) 267 0 0 0 Other comprehensive (loss) income $ 1,185 $ (174 ) $ 1,011 $ (1,295 ) $ 88 $ (1,207 )

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended March 31, (In thousands) 2016 2015 Revenue: Clinical and Financial Solutions $ 271,654 $ 263,875 Population Health 66,383 64,948 Unallocated Amounts 7,521 5,729 Total revenue $ 345,558 $ 334,552 Gross Profit: Clinical and Financial Solutions $ 114,200 $ 98,273 Population Health 48,995 43,199 Unallocated Amounts (11,297 ) (11,682 ) Total gross profit $ 151,898 $ 129,790 Income (loss) from operations: Clinical and Financial Solutions $ 61,017 $ 43,185 Population Health 32,834 26,247 Unallocated Amounts (81,955 ) (75,127 ) Total income (loss) from operations $ 11,896 $ (5,695 )

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 99,127	$ 93,622
Accrued expenses	(56,007)	(62,021)
Total	54	(578)
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	866	424
Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(49,817)	(81,210)
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	49,005	80,208
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	0	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	866	424
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	866	424
Level 2 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	(812)	(1,002)
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(49,817)	(81,210)
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 49,005	$ 80,208

Summary of Equity Investments I

Summary of Equity Investments Included in Other Assets (Detail) $ in Thousands		3 Months Ended
		Mar. 31, 2016USD ($)Investment	Dec. 31, 2015USD ($)
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1]	4
Equity method investments, Original Investment	[1]	$ 207,051
Equity method investments, Carrying Value	[1]	$ 202,950	$ 205,553
Cost method investments, Number of Investees | Investment		3
Cost method investments, Original Investment		$ 19,776
Cost method investments, Carrying Value		$ 15,826	17,876
Total equity investments, Number of Investees | Investment		7
Total equity investments, Original Investment		$ 226,827
Total equity investments, Carrying Value		$ 218,776	223,429
Nant Health, LLC [Member]
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1]	1
Equity method investments, Original Investment	[1]	$ 205,393
Equity method investments, Carrying Value	[1]	$ 200,514	203,117
Other [Member]
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1]	3
Equity method investments, Original Investment	[1]	$ 1,658
Equity method investments, Carrying Value	[1]	$ 2,436	$ 2,436
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and I32

Fair Value Measurements and Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Equity method investments equity share net losses	$ (2,603)	$ 0
Asset impairment charges	4,650	$ 26
Total consideration for non marketable equity securities	$ 500
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%
Other Assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Convertible note fair value	$ 500
Cost Method Equity Investments
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Asset impairment charges	2,100
Nant Health, LLC [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Equity method investments equity share net losses	(2,600)
Equity method investment, underlying equity of net assets	$ 182,000

Summarized Financial Informatio

Summarized Financial Information for Equity Method Investments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015
Equity Method Investments And Joint Ventures [Abstract]
Current assets	$ 42,239		$ 58,550
Noncurrent assets	397,519		411,159
Current liabilities	52,482		77,188
Noncurrent liabilities	191,563		166,898
Equity of equity method investments	195,713		$ 225,623
Revenue	23,336	$ 2,470
Net loss	$ (24,540)	$ (216)

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Nov. 30, 2015
Equity [Abstract]
Stock options granted	0	0
Capitalized stock-based compensation costs	$ 0	$ 0
Share issued, exercise of options and release of stock awards	600,000		1,400,000
Shares settled for tax withholding	323,000	179,000
Stock repurchase program, authorized amount				$ 150,000,000
Common stock repurchased, shares	2,900,000
Common stock repurchased, amount	$ 37,517,000	$ 0
Remaining value for purchase of common stock under the stock repurchase program	$ 112,500,000

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 10,401	$ 9,518
Cost of revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	2,659	2,504
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	1,169	1,096
Cost of revenue [Member] | Client services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	1,490	1,408
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	5,166	5,011
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 2,576	$ 2,003

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, granted | shares	2,968
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 13.07
Service-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, granted | shares	1,802
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 13.13
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, granted | shares	545
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 12.39
Market-Based Restricted Stock Units with a Service Condition [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, granted | shares	621
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 13.49

Calculations of Earnings (Loss)

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Basic Earnings (Loss) per Common Share:
Net income (loss)	$ 2,127	$ (10,084)
Less: Net income attributable to non-controlling interest	(78)	0
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 2,049	$ (10,084)
Weighted-average common shares outstanding	188,561	180,581
Basic Earnings (Loss) per Common Share	$ 0.01	$ (0.06)
Diluted Earnings (Loss) per Common Share:
Net income (loss)	$ 2,127	$ (10,084)
Less: Net income attributable to non-controlling interest	(78)	0
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 2,049	$ (10,084)
Weighted-average common shares outstanding	188,561	180,581
Dilutive effect of stock options, restricted stock unit awards and warrants	2,180	0
Weighted-average common shares outstanding assuming dilution	190,741	180,581
Diluted Earnings (Loss) per Common Share	$ 0.01	$ (0.06)

Anti-Dilutive Stock Options, Re

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	25,201	25,144

Goodwill and Intangible Asset39

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,002,892	$ 1,003,247
Accumulated Amortization	(719,170)	(707,601)
Intangible Assets, Net	283,722	295,646
Registered trademarks	52,000	52,000
Goodwill	1,222,283	1,222,601
Total	1,274,283	1,274,601
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	450,692	450,852
Accumulated Amortization	(309,721)	(302,284)
Intangible Assets, Net	140,971	148,568
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	552,200	552,395
Accumulated Amortization	(409,449)	(405,317)
Intangible Assets, Net	$ 142,751	$ 147,078

Changes in Carrying Amount of G

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill [Line Items]
Goodwill	$ 1,222,601
Foreign exchange translation	(318)
Goodwill, net	1,222,283
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	796,367
Foreign exchange translation	(318)
Goodwill, net	796,049
Population Health [Member]
Goodwill [Line Items]
Goodwill	426,234
Foreign exchange translation	0
Goodwill, net	$ 426,234

Goodwill and Intangible Asset41

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 0	$ 0

Asset Impairment Charges - Addi

Asset Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Asset Impairment Charges [Line Items]
Asset impairment charges	$ 4,650	$ 26
Other charges	400
Capitalized Software Development Projects [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges	2,200
Cost Method Equity Investments
Asset Impairment Charges [Line Items]
Asset impairment charges	$ 2,100

Debt Outstanding Excluding Capi

Debt Outstanding Excluding Capital Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2016		Dec. 31, 2015
Debt Instrument [Line Items]
Principal Balance	$ 663,894		$ 692,058
Unamortized Discount and Debt Issuance Costs	64,368		67,475
Net Carrying Amount	599,526		624,583
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	[1]	345,000
Unamortized Discount and Debt Issuance Costs	58,663		61,771
Net Carrying Amount	286,337		283,229
Senior Secured Credit Facility (long-term portion) [Member]
Debt Instrument [Line Items]
Principal Balance	306,250		334,375
Unamortized Discount and Debt Issuance Costs	5,232		5,225
Net Carrying Amount	301,018		329,150
Senior Secured Credit Facility (current portion) [Member]
Debt Instrument [Line Items]
Principal Balance	12,500		12,500
Unamortized Discount and Debt Issuance Costs	473		479
Net Carrying Amount	12,027		12,021
Other Debt [Member]
Debt Instrument [Line Items]
Principal Balance	144		183
Unamortized Discount and Debt Issuance Costs	0		0
Net Carrying Amount	$ 144		$ 183
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail)

Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Disclosure [Abstract]
Interest expense	$ 3,538	$ 3,861
Amortization of discounts and debt issuance costs	3,431	3,395
Total interest expense	$ 6,969	$ 7,256

Interest Expense Related to Not

Interest Expense Related to Notes (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 3,538	$ 3,861
Amortization of discounts and debt issuance costs	3,431	3,395
Total interest expense	6,969	7,256
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Coupon interest at 1.25%	1,078	1,078
Amortization of discounts and debt issuance costs	3,108	2,948
Total interest expense	$ 4,186	$ 4,026

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016		Dec. 31, 2015
Debt Instrument [Line Items]
Debt instrument principal amount	$ 663,894		$ 692,058
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, fees and aggregate cost	300
Debt issuance costs	300
Letters of credit outstanding	$ 700
Senior Secured Credit Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	2.18%
Senior Secured Credit Facility [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread	1.75%
Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	$ 243,750
Revolving credit facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	75,000
Credit facility, amount available	474,300
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	$ 345,000	[1]	$ 345,000
Interest rate	1.25%
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Payment Oblig

Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities (Detail) - USD ($) $ in Thousands		Mar. 31, 2016		Dec. 31, 2015
Debt Instrument [Line Items]
Total		$ 663,894		$ 692,058
Remainder of 2016		9,519
2,017		15,625
2,018		28,125
2,019		40,625
2,020		570,000
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total		345,000	[1]	345,000
Remainder of 2016	[1]	0
2,017	[1]	0
2,018	[1]	0
2,019	[1]	0
2,020	[1]	345,000
Term Loan [Member]
Debt Instrument [Line Items]
Total		243,750
Remainder of 2016		9,375
2,017		15,625
2,018		28,125
2,019		40,625
2,020		150,000
Other Debt [Member]
Debt Instrument [Line Items]
Total		144		$ 183
Remainder of 2016		144
2,017		0
2,018		0
2,019		0
2,020		0
Revolving Facility [Member]
Debt Instrument [Line Items]
Total		75,000
Remainder of 2016		0
2,017		0
2,018		0
2,019		0
2,020		$ 75,000
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Payment Obl48

Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2016
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Notes maturity period	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income (loss) before income taxes	$ 2,690	$ (11,065)
Income tax (provision) benefit	$ (563)	$ 981
Effective tax rate	20.90%	8.90%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Cumulative operating income loss period considered	3 years
Valuation allowance	$ 0.9
Unrecognized income tax benefits	$ 12.3	$ 11.8

Fair Value and Balance Sheet Lo

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 49,871	$ 80,632
Derivative liability, fair value	49,817	81,210
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	866	424
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	49,005	80,208
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 49,817	$ 81,210

Derivative Financial Instrume52

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016USD ($)Derivative	Mar. 31, 2016INR (₨)Derivative	Jun. 30, 2015USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Interest rate	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	30	30
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ 0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income	$ 700,000
Estimated period of unrealized gains included in AOCI reclassified into income	12 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Apr. 30, 2016
Derivative notional amount outstanding	$ 300,000	₨ 20,000,000
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Dec. 31, 2017
Derivative notional amount outstanding	$ 2,100,000	₨ 140,000,000
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Interest rate	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option			$ 82,800,000

Derivatives Instruments Designa

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ 342	$ 0
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	(31)	0
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	(25)	0
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ (43)	$ 0

Net Impact of Changes in Fair V

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ 190	$ 25
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	31,393	7,234
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ (31,203)	$ (7,209)

Components of Accumulated Other

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	$ (4,242)	$ (1,979)
Other comprehensive (loss) income before reclassifications	951	(1,067)
Net losses (gains) reclassified from accumulated other comprehensive loss	60	(140)
Total other comprehensive income (loss)	1,011	(1,207)
Balance at the end of the period	(3,231)	(3,186)
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(4,500)	(2,119)
Other comprehensive (loss) income before reclassifications	744	(1,067)
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0
Total other comprehensive income (loss)	744	(1,067)
Balance at the end of the period	(3,756)	(3,186)
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	0	140
Other comprehensive (loss) income before reclassifications	0	0
Net losses (gains) reclassified from accumulated other comprehensive loss	0	(140)
Total other comprehensive income (loss)	0	(140)
Balance at the end of the period	0	0
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	258	0
Other comprehensive (loss) income before reclassifications	207	0
Net losses (gains) reclassified from accumulated other comprehensive loss	60	0
Total other comprehensive income (loss)	267	0
Balance at the end of the period	$ 525	$ 0

Components of Accumulated Oth56

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 340	$ 166
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)			$ 88

Income Tax Effects Related to C

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 744	$ (1,067)
Net change in unrealized gains on marketable securities, Before-Tax Amount	0	228
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	441	0
Other comprehensive (loss) income, Before-Tax Amount	1,185	(1,295)
Foreign currency translation adjustments, Tax Effect	0	0
Other comprehensive (loss) income, Tax Effect	(174)	88
Foreign currency translation adjustments, Net	744	(1,067)
Other comprehensive (loss) income, Net	1,011	(1,207)
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Marketable securities, net gain arising during the period, Before-Tax Amount	0	0
Marketable securities, net gain reclassified into income, Before-Tax Amount	0	(228)
Net change in unrealized gains on marketable securities, Before-Tax Amount	0	(228)
Marketable securities, net gain arising during the period, Tax Effect	0	0
Marketable securities, net gain reclassified into income, Tax Effect	0	88
Net change in unrealized gains on marketable securities, Tax Effect	0	88
Marketable securities, net gain arising during the period, Net	0	0
Marketable securities, net gain reclassified into income, Net	0	(140)
Net change in unrealized gains on marketable securities, Net	0	(140)
Other comprehensive (loss) income, Net	0	(140)
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	441	0
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(174)	0
Derivatives qualifying as cash flow hedges, net gain (loss), Net	267	0
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount	342	0
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	99	0
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	441	0
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	(135)	0
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	(39)	0
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(174)	0
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	207	0
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	60	0
Derivatives qualifying as cash flow hedges, net gain (loss), Net	267	0
Other comprehensive (loss) income, Net	$ 267	$ 0

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Pending Litigation [Member] - $ / Violation	3 Months Ended
	Mar. 31, 2016	May. 01, 2012
Pegasus Imaging Corporation [Member]
Loss Contingencies [Line Items]
Contingency allegations	The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence.
Loss contingency action taken by defendant	Counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation.
Physicians Healthsource Inc [Member]
Loss Contingencies [Line Items]
Damages sought per alleged violation of the TCPA		500

Business Segments - Additional

Business Segments - Additional Information (Detail) - Segment	Jan. 01, 2016	Mar. 31, 2016
Segment Reporting [Abstract]
Number of reportable segments		2
Number of operating segments	4

Revenues and Income from Operat

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 345,558	$ 334,552
Gross Profit	151,898	129,790
Income (loss) from operations	11,896	(5,695)
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	7,521	5,729
Gross Profit	(11,297)	(11,682)
Income (loss) from operations	(81,955)	(75,127)
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	271,654	263,875
Gross Profit	114,200	98,273
Income (loss) from operations	61,017	43,185
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	66,383	64,948
Gross Profit	48,995	43,199
Income (loss) from operations	$ 32,834	$ 26,247

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Contribution and investment agreement date	Mar. 20, 2016
Joint venture completion date	Apr. 19, 2016